Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study of IAM1363 in Participants With Advanced Cancers Harboring HER2 Alterations

NCT06253871 is registered in ClinicalTrials.gov with Iambic Therapeutics, Inc as lead sponsor.

NCT NCT06253871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06253871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study of IAM1363 in Participants With Advanced Cancers Harboring HER2 Alterations
Lead sponsor
Iambic Therapeutics, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
March 25, 2024
Completion date
December 31, 2028
Enrollment
383 (estimated)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases from her2 and breast cancer, brain metastases from solid tumors, cns metastases, her2, her2 + breast cancer, her2 + gastric cancer, her2 mutation-related tumors, her2-positive bladder cancer, her2-positive breast cancer, her2-positive colorectal cancer, her2-positive gastroesophageal cancer, her2-positive solid tumors, nsclc (non-small cell lung cancer)